Share this link via:
Add Citation
Global Industry Hub. (Sep, 2024). Blood-based Biomarker For Sports Medicine Market Share & Forecast, 2024 - 2030 Global Industry Hub. Retrieved
Report ID: GIH 1041 | Sep 2024 | Format:
Request CustomizationShare this link via:
Add Citation
Global Industry Hub. (Sep, 2024). Blood-based Biomarker For Sports Medicine Market Share & Forecast, 2024 - 2030 Global Industry Hub. Retrieved
Blood-based Biomarker For Sports Medicine Market size was valued at US$ 665.5 Mn in 2023, registering a CAGR of 6.8% during the forecast period (2024-2030), and the market is projected to be worth US$ 1.22 Bn by 2030.
The report includes Vendor Assessment (Company Profiles, Market Positioning, Strategies, Recent Market Updates, Capabilities & Product Offerings / Mapping), Technology Assessment (Developments & Economic Impact), Partner & Customer Ecosystem (Product Services, Proposition & Key Features) Competitive Index & Regional Footprint by Global Industry Hub.
Blood-based Biomarker For Sports Medicine Market Scope:
The Blood-based Biomarker For Sports Medicine market is divided based on product, end user, application, and region. Each category has various sub-segments, and current trends in each segment help producers target specific customers effectively.
Important Features of the Report:
Reasons for buying this report:
Type Outlook
CK
Myoglobin
Lactate
WBC
Urea
CRP
Lipid And Protein Hydroperoxides
IL-6
Others
Regional Outlook
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
New Zealand
Taiwan
Hong Kong
Singapore
Thailand
Vietnam
Latin America
Brazil
Argentina
Chile
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Egypt
Qatar
Key players in the industry are adopting growth strategies like partnerships, collaborations, mergers and acquisitions, and awareness programs to strengthen their market presence. The report also lists industry players for end users, facilitating communication between manufacturers and consumers.
In October 2023, BIOMÉRIEUX announced the CE-marking of VIDAS TBI, a blood test designed to assist in assessing patients with mild Traumatic Brain Injury (TBI). This test utilizes a distinctive set of brain biomarkers, including GFAP and UCH-L1, to provide its analysis.
In February 2023, Roche broadened its collaboration with Janssen to further advance personalized healthcare through companion diagnostics. The new agreement extended their efforts to encompass a wide range of companion diagnostics, including both tissue and blood-based biomarkers.
Updated Version & Immediate Delivery Available
You'll get the sample you asked for by email. Remember to check your spam folder as well. If you have any further questions or require additional assistance, feel free to let us know via-
03 Sep 2024 This Report Contains the Latest Market Numbers, Statistics & Data Aavailable